CLN 101 PPT

GROUP 5
VAIBHAV JAISWAL 2017CH10232

SUPRIYA RANGA 2017CH10256

SOHAM DIALANI 2017CH10204
POINTS TO BE CONCLUDED FROM PREVIOUS
PRESENTATION
The solutions we proposed in our previous ppt was that Indian Pharmaceutical Companies can grow if we
do the following things:
• “Track and Track Sensors” should be used to enforce serialisation, non- cloneable packaging and 2D
barcoding.
• Drug sensor app can be used to monitor the drug control in a better way.
• Use of digital technology and installation of CRM Systems can be done so as to ensure good services of
medicines to the customers.
• New Practices and techniques need to be developed by R&D (Research and Development) Dept.
WHAT TO ADDRESS NEXT ?...........
TOPIC OF DISCUSSION : HOW CAN FUNDING OF
R&D CAN BE IMPROVED?
• Existing global funding instruments for health, including the Global Fund, GAVI, and UNITAID,
could expand their mandate to include funding for R&D through grants to PDPs and grants or
loans to biopharma organizations .
• Capital could be raised through government-backed bonds with the bond proceeds deposited
in a special facility to support the R&D activities of PDPs, and with royalties on product sales
used to repay part or all other bonds.
• Cash prizes could be offered to reward partial progress and significant achievements on the
road to develop new drugs, vaccines, and diagnostic tests .
• The government is planning to set up a Rs 10,000-crore venture capital (VC) fund for
financing new drug discovery projects in the country, reports PTI.
• Governments have long used direct funding to
stimulate firms’ R&D through various instruments,
including matching grants, subsidized loans, and
venture capital and seed funds. Besides basic research
and product development, eligible activities for funding
may also include training, process innovation,
technology commercialization, early stage funding for
technology start-ups, etc. Public funding covers a
variable proportion of the costs of an R&D project,
requiring co-financing by beneficiary firms.
• There is a lot of investment in R & D by IPI ( International Pharmaceutical Industries ).
Companies spend money on R&D, not only for the growth of the market but also to
strengthen their positions. But, the problem is that these investments should be further
exceeded . The IPI is still waiting for its first indigenous new product launch.
• FUNDING BY THE PRIVATE SECTOR : According to information available, the country
spends about Rs2,000 crore every year on R&D. While the government contributes Rs500
crore to this, the rest comes from the private sector. The proposed funding of Rs10,000 crore,
which includes substantial contribution from the private pharma industry under the PPP
model, is likely to bring about a favorable environment for drug innovation. Last year, the
Department of Pharmaceuticals had prepared a white paper on promoting R&D funding in
the country, and submitted the proposal to the Prime Minister's Office (PMO) for approval.
GRAPH : R & D SPENDING IN LAST FEW YEARS
CHALLENGES TO SOLUTIONS PROPOSED

• Collaboration with other pharmaceutical companies, outsource partners, suppliers,

distributors, and government agencies further complicates data management. With more
players involved in the R&D process, pharmaceutical companies have to manage data sets
coming from a larger number of databases inside and outside of their four walls.
• Security risks are even higher with collaboration. Researchers and scientists or other
collaborators require access to confidential information such as a patient’s personal
health information (PHI) from clinical testing or health histories. This inherently increases
the risks of critical information getting compromised as there are a greater number of
data transfers and sharing.
INNOVATIONS AS A SOLUTION TO THESE
CHALLENGES :
• Clinical Data Management (CDM) solutions help pharmaceutical and research companies
to ensure the quality of their data. CDM solutions also help pharmaceutical companies
secure and protect patient records and clinical trial participants’ data.
• CDM delivers quality data and outcomes to pharmaceutical companies and other life
sciences organizations. With a three-step process of collection, cleaning, and managing
data, CDM gathers the maximum amount of data for analysis and ensures that the data is
of the highest quality and integrity for statistical analysis by minimizing errors and
instances of missing data.
GLOBAL EFFORTS TO IMPROVE
PHARMACEUTICAL R&D
• The WHO established the Consultative Expert Working Group on Co-ordination and
Financing of Biomedical R&D (CEWG) to develop recommendations for financing and
coordinating new R&D incentives. The expert group has emphasized the importance of
open knowledge innovation and de-linking the cost of R&D from the price of a medicine.
REFERENCES

• https://www.liaison.com/blog/2017/04/07/pharmaceutical-rd-process-inherent-data-
challenges/
• https://www.ft.com/content/4c99afa0-6279-11e7-8814-0ac7eb84e5f1
• https://www.businesstoday.in/opinion/deep-dive/expert-view-pharmaceutical-companies-
india-challenges-growth/story/202812.html
• https://www.innovationpolicyplatform.org/content/direct-funding-firms-rd